On Friday 24 June, the European Commission granted Valneva a conditional marketing authorisation for its adjuvanted inactivated whole virus SARS-CoV-2 vaccine (VLA2001).
The authorisation, valid for one year and renewable, was formally granted by the European Commission following the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 23 June (see EUROPE B12979A25). The licence was issued for use in 18-50 year...